Let's talk about ageing
As we age, our immune system weakens, leaving us more susceptible to diseases.1
There is a gap in immunisation coverage between adults and infants.2,3 Vaccination is key to healthy aging and there is a need to focus on reducing this gap in coverage.2,3
How can you help?
Recommendation from a health professional was shown to be the most important factor influencing adults receiving a vaccine.2-4 In Australia, when consumers were asked where they sought information on vaccination, consumers consistently cited their GPs as a reliable resource.3
Build your knowledge on healthy ageing, immunisation, and vaccine-preventable diseases through this 4-part CPD accredited webinar series
of Australians are aged
>50 years old5
20% of Australians have ≥2 chronic health conditions (multimorbidity)6
Join us for the Healthy Immune Ageing CPD webinar series
There were nearly 8.5 million people in Australia aged ≥ 50 years in 20215 highlighting the importance of understanding health in an ageing population.
Join us for a discussion with Dr Sarah Chu and Dr Daman Langguth about healthy ageing and the impact that ageing has on both an individual’s susceptibility to infectious diseases and decreased response to vaccination.6
Risks of vaccine-preventable conditions in older adults with multi-morbidities
As people age, they accrue multiple co-morbidities.5 This can increase the risk of developing infectious diseases and associated complications.
Hear from Dr Rodney Pearce and Dr Paul Russo as they exemplify these risks through their respective case presentations about a delayed diagnosis of pertussis and the devastating impact of zoster radiculitis in an elderly patient with multi-morbidities.8
Seizing opportunities to reduce infectious disease risk in older adults with respiratory comorbidities
As people age, they often develop multi-morbidities which may place them at increased risk of disease.7
Learn from Dr Victoria Hayes and Associate Professor Michael Woodward as they put a spotlight on chronic obstructive pulmonary disease (COPD) and asthma and the impact of immunosenescence on increased risk of herpes zoster, while seizing opportunities in practice to increase vaccination uptake.8
Empowering older adults with cardiovascular disease to reduce vaccine-preventable disease risk
The progressive accrual of chronic conditions as people age may place them at increased risk of vaccine-preventable diseases.6
Join Dr Sarah Chu and Dr Anthony French as they focus on the relationship between
cardiovascular disease and vaccine-preventable diseases, and how we can better empower patients to make decisions to reduce their vaccine-preventable disease risk.
Speakers involved in the series
Get to know the subject-matter experts involved in our four-part series
1. Aiello A, Farzaneh F, Candore G, et al. Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention. Front Immunol. 2019 Sep 25;10:2247.
2. Menzies RI, Leask J, Royle J, MacIntyre CR. Vaccine myopia: adult vaccination also needs attention. Med J Aust. 2017 Apr 3;206(6):238-239.
3. Bayliss J, Randhawa R, Oh KB, et al. Perceptions of vaccine preventable diseases in Australian healthcare: focus on pertussis. Hum Vaccin Immunother. 2021 Feb 1;17(2):344-350.
4. Magin P, van Driel ML. Immunising older Australians: Pre-COVID-19 vaccine perspectives from general practice training. AJGP Vol. 50, No. 6, June 2021.
5. Australian Bureau of Statustics. Population: Census, information on sex and age. Table for Population data summary, ABS 2021. Available here. Accessed May 2023
6. Australian Institute of Health and Welfare. Chronic conditions and multimorbidities. 2022. Accessed May 2023. Available here
7. Australian Institute of Health and Welfare. The burden of vaccine preventable diseases in Australia. 2019. Accessed May 2023. Available here
8. Xu W, Wong G, Hwang YY, Larbi A. The untwining of immunosenescence and aging. Semin Immunopathol. 2020 Oct;42(5):559-572. doi: 10.1007/s00281-020-00824-x.
These educational activities were developed by Lateral Connections at the request of and with funding from GlaxoSmithKline PTY LTD (Melbourne, Victoria)
NX-AU-SGX-WCNT-220007 Date of approval: June 2023